DBV Technologies Expands Board of Directors

23-Feb-2009 - France

DBV Technologies (DBV), a biopharmaceutical company specialising in the development of non-invasive epicutaneous diagnostics and immunotherapies for allergies, announced that it has expanded its Board of Directors with the appointment of Peter Barton Hutt as Non-Executive Director.

Hutt brings extensive knowledge and first-hand experience of US food and drug legislation to DBV. He is currently a senior counsel in the Washington DC law firm of Covington & Burling LLP, specialising in Food and Drug Law, and teaching a full course on Food and Drug Law at Harvard Law School each year. He has been a member of the US Institute of Medicine since its establishment in 1971 and was formerly Chief Counsel for the US Food and Drug Administration.

According to the company, this board appointment is of strategic importance as DBV works towards a Phase I study for peanut allergy desensitization in the US.

Other news from the department people

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures